

RECEIVED

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANTATTORNEY'S DKT NO.
033053-025APPLICATION NO.
09/972,425APPLICANT
Kenneth C. Cundy, et al.FILING DATE
October 5, 2001GROUP
1614

JAN 3 0 2002

FEB 1 2002
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS				
Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)
	Number	Kind Code (if known)		
BB	5,541,348		Araya, et al.	7/30/1996
	5,462,933		Kramer, et al.	10/31/1995
	5,646,272		Kramer, et al.	7/8/1997
	5,668,126		Kramer, et al.	9/16/1997
	4,024,175		Satzinger	5/17/1977
	5,563,175		Silverman	10/8/1996
	5,684,018		Alexander	11/4/1997
	6,020,370		Horwell	2/1/2000
	6,028,214		Silverman	2/22/2000
	6,103,932		Horwell	8/15/2000
BB	6,117,906		Silverman	9/12/2000

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	No
BB	WO92/09560		PCT	6/11/1992		
	WO93/23383		PCT	11/25/1993		
	WO97/29101		PCT	8/14/1997		
	WO97/33858		PCT	9/18/1997		
	WO97/33859		PCT	9/18/1997		
	WO98/17627		PCT	4/30/1998		
	WO99/08671		PCT			
	WO99/21824		PCT	5/6/1999		
	WO99/31057		PCT	6/24/1999		
	WO99/31074		PCT	6/24/1999		
	WO99/31075		PCT	6/24/1999		
	WO99/61424		PCT	12/2/1999		
	WO00/15611		PCT	3/23/2000		
	WO00/23067		PCT	4/27/2000		
	WO00/31020		PCT	6/2/2000		
	WO00/50027		PCT	8/31/2000		
BB	0 272 462B1		Europe	6/29/1998		

NON PATENT LITERATURE DOCUMENTS	
BB Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

ATTORNEY'S DKT NO. 033053-025	APPLICATION NO. 09/972,425
APPLICANT Kenneth C. Cundy, et al.	
FILING DATE October 5, 2001	GROUP 1614

FEB 01 2002

1600/1600

RECEIVED



	Baringhaus, K.-H.; Matter, H.; Stengelin, S.; Kramer, W. Substrate specificity of the ileal and hepatic Na^+ / bile acid cotransporters of the rabbit. II. A reliable 3D QSAR pharmacophore model for the ileal Na^+ / bile acid cotransporter. <i>J. Lipid Res.</i> 1999 , <i>40</i> , pp. 2158-2168.
	Batta, et al., <i>J. Lipid Res.</i> , 1991 , <i>32</i> , pp. 977-983
	Bryans, J. S.; Wustrow, D. J. 3-Substituted GABA analogs with central nervous system activity: a review. <i>Med. Res. Rev.</i> 1999 , <i>19</i> , pp. 149-177.
	Bundgaard, H. in <i>Design of Prodrugs</i> (Bundgaard, H. Ed.), Elsevier Science B.V., 1985 , pp. 1-92.
	Ho, N. F. H. Utilizing bile acid carrier mechanisms to enhance liver and small intestine absorption. <i>Ann. N. Y. Acad. Sci.</i> 1987 , <i>507</i> , pp. 315-329.
	Jezyk, N.; Li, C.; Stewart, B. H.; Wu, X.; Bockbrader, H. N.; Fleisher, D. Transport of pregabalin in rat intestine and Caco-2 monolayers. <i>Pharm. Res.</i> 1999 , <i>16</i> , pp. 519-526.
	Kagedahl, M.; Swaan, P. W.; Redemann, C. T.; Tang, M.; Craik, C. S.; Szoka, F. C.; Oie, S. Use of the intestinal bile acid transporter for the uptake of cholic acid conjugates with HIV-1 protease inhibitory activity. <i>Pharm. Res.</i> 1997 , <i>14</i> , pp. 176-180.
	Kim, D.C., et al., Evaluation of bile acid transporter in enhancing intestinal permeability of renin-inhibitory peptides, <i>J. Drug Targeting</i> , 1993 , <i>1</i> , pp. 347-359.
	Kramer, W.; Wess, G.; Schubert, G.; Bickel, M.; Girbig, F.; Gutjahr, U.; Kowalewski, S.; Baringhaus, K.-H.; Enhsen, A.; Glombik, H.; Mullner, S.; Neckermann, G.; Schulz, S.; Petzinger, E. Liver-specific drug targeting by coupling to bile acids. <i>J. Biol. Chem.</i> 1992 , <i>267</i> , pp. 18598-18604.
	Kramer, W.; Wess, G.; Neckermann, G.; Schubert, G.; Fink, J.; Girbig, F.; Gutjahr, U.; Kowalewski, S.; Baringhaus, K.-H.; Boger, G.; Enhsen, A.; Falk, E.; Friedrich, M.; Glombik, H.; Hoffmann, A.; Pittius, C.; Urmann, M. Intestinal absorption of peptides by coupling to bile acids. <i>J. Biol. Chem.</i> 1994a , <i>269</i> , pp. 10621-10627.
	Kramer, W.; Wess, G.; Enhsen, A.; Bock, K.; Falk, E.; Hoffmann, A.; Neckerman, G.; Gantz, D.; Schulz, S.; Nickau, L.; Petzinger, E.; Turley, S.; Dietschy, J. M. Bile acid derived HMG-CoA reductase inhibitors. <i>Biochim. Biophys. Acta</i> 1994b , <i>1227</i> , pp. 137-154.
	Kramer, W.; Stengelin, S.; Baringhaus, K.-H.; Enhsen, A.; Heuer, H.; Becker, W.; Corsiero, D.; Girbig, F.; Noll, R.; Weyland, C. Substrate specificity of the ileal and hepatic Na^+ / bile acid cotransporters of the rabbit. I. Transport studies with membrane vesicles and cell lines expressing the cloned transporters. <i>J. Lipid Res.</i> 1999 , <i>40</i> , pp. 1604-1617.
	Kullak-Ublick, G. A.; Beuers, U.; Paumgartner, G. Hepatobiliary transport. <i>J. Hepatology</i> 2000 , <i>32 (Suppl. 1)</i> , pp. 3-18
	Navia, M. A.; Chaturvedi, P. R. Design principles for orally bioavailable drugs. <i>Drug Discovery Today</i> 1996 , <i>1</i> , pp. 179-189
	Petzinger, E.; Nickau, L.; Horz, J. A.; Schulz, S.; Wess, G.; Enhsen, A.; Falk, E.; Baringhaus, H.; K. Glombik, H.; Hoffmann, A.; Mullner, S.; Neckermann, G.; Kramer, W. Hepatobiliary transport of hepatic 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors conjugated with bile acids., <i>Hepatology</i> 1995 , <i>22</i> , pp. 1801-1811.
	Swaan, P. W.; Szoka, F. C.; Oie, S. Use of the intestinal and hepatic bile acid transporters for drug delivery. <i>Adv. Drug Delivery Rev.</i> 1996 , <i>20</i> , pp. 59-82.
BB	Tsujii, A.; Tamai, I. Carrier-mediated intestinal transport of drugs. <i>Pharm. Res.</i> 1996 , <i>13</i> , pp. 963-977.

Examiner
Signature

Padis

Date
Considered

4/30/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO	ATTORNEY'S DKT NO. 033053-025	APPLICATION NO. 09/972,425
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Kenneth C. Cundy, et al.	
	FILING DATE October 5, 2001	GROUP 1614



U.S. PATENT DOCUMENTS

RECEIVED
JULY 2001

~~MAR 06 2002~~

~~TECH CENTER 160012500~~

FOREIGN PATENT DOCUMENTS

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
Examiner Signature	Bardis	Date Considered	4/30/03

1000

Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

Examiner
Signature

Badiw

Date
Considered

4/30/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance **and** not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO

ATTORNEY'S DKT NO.
033053-025APPLICATION NO.
09/972,425INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Kenneth C. Cundy, et al.FILING DATE
October 5, 2001GROUP
1614

U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)
	Number	Kind Code (if known)		
BP	4,508,728		Nagai et al.	4/2/85
	4,908,353		Yamamoto et al.	3/13/90
	5,094,848		Brixner	3/10.92
	5,110,797		Ienaga et al.	5/5/92
BB	6,051,683		Deigin et al.	4/19/2000
RECEIVED				
AUG 28 2002				
TECH CENTER 1600/2900				

FOREIGN PATENT DOCUMENTS

Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation
	Number	Kind Code (if known)			
X	SU285929		Soviet Union	1/13/71	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
Examiner Signature	Badie	Date Considered	4/30/03

* English translation needed.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.